RBC Capital Lowers Its Price Target on Viridian Therapeutics, Inc. (VRDN) to $42 and Maintains an Outperform Rating

Viridian Therapeutics, Inc. (NASDAQ:VRDN) is among the 10 Fastest Growing NASDAQ Stocks to Buy.

On February 27, 2026, RBC Capital lowered its price target on Viridian Therapeutics, Inc. (NASDAQ:VRDN) to $42 from $45 and maintained an Outperform rating. The analyst noted the company reported Q4 EPS and disclosed that veli’ PDUFA is scheduled for June 30, with preparations underway for a potential commercial launch in thyroid eye disease in mid-2026 if approved. RBC said it continues to favor the company’s positioning in 2026 as it could transition to the commercial stage and move closer to profitability.

On February 26, 2026, Jefferies raised its price target to $45 from $44 and kept a Buy rating. The firm said all key events remain on track and that investor focus is on the Phase 3 topline readout of subcutaneous elegrobart in REVEAL-1 in Q1, REVEAL-2 in Q2, and the PDUFA decision due June 30 for intravenous veligrotug under priority review.

That same day, Viridian Therapeutics reported Q4 EPS of ($1.08), compared to the ($1.00) consensus estimate. Q4 revenue was $132,000 versus the consensus of $15.75M. President and Chief Executive Officer Steve Mahoney said the company enters 2026 with continued execution momentum, highlighting the veligrotug BLA filing under Priority Review and a June 30, 2026, PDUFA target date. He added that the MAA submission to the EMA supports the global opportunity for veligrotug and that REVEAL-1 topline data for elegrobart is expected next month, with the goal of establishing veligrotug and elegrobart as foundational therapies for TED while advancing the broader pipeline.

Viridian Therapeutics, Inc. (NASDAQ:VRDN) discovers, develops, and commercializes treatments for serious and rare diseases, including IGF-1R therapies for thyroid eye disease.

While we acknowledge the potential of VRDN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Best Tech Stocks that Beat Earnings Estimates and 40 Most Popular Stocks Among Hedge Funds Heading Into 2026

Disclosure: None. Follow Insider Monkey on Google News.